Craft

EDAP TMS

Stock Price

$3

2024-10-29

Market Capitalization

$111.3 M

2024-10-29

Revenue

€70.5 M

FY, 2025

EDAP TMS Summary

Company Summary

Overview
EDAP TMS is a company that develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology. It offers products for the treatment of certain types of urological disorders, including the ablation of localized prostate cancer tumors using HIFU (High Intensity Focused Ultrasound) technology and the removal of urinary tract stones using ESWL (Extracorporeal ShockWave Lithotripsy).
Type
Public
Status
Active
Founded
1979
HQ
Vaulx-en-Velin, FR | view all locations
Website
https://investor.focalone.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Pierre Beysson, Director

    • Marc Oczachowski

      Marc Oczachowski, CEO, Chairman Of The Board

    • François Dietsch, Chief Financial Officer

    • Frédéric Pech, Chief Operating Officer

      LocationsView all

      8 locations detected

      • Vaulx-en-Velin, Auvergne-Rhône-Alpes HQ

        France

        4 Rue du Dauphiné

      • Austin, TX

        United States

        5321 Industrial Oaks Blvd #110

      • Flensburg, SH

        Germany

        Holm 19 - 21

      • Chuo City, Tōkyō-to

        Japan

        1-chōme-3-17 Shinkawa

      • Subang Jaya, Selangor

        Malaysia

        1, 3 & 5, Jalan USJ 10/1a, Taipan Business Centre

      • Moscow

        Russian Federation

      and 2 others

      EDAP TMS Financials

      Summary Financials

      Revenue (FY, 2025)
      €70.5M
      Gross profit (FY, 2025)
      €33.4M
      Net income (FY, 2025)
      (€29.2M)
      Cash (FY, 2025)
      €20.5M
      EBIT (FY, 2025)
      (€24.7M)
      Enterprise value
      $115.5M

      Footer menu